Figure 1. Consort Diagram of Patient Disposition.

Patients excluded due to insufficient visit data did not have a baseline visit (with the EDSS score recorded) within an interval of 180 days before or 30 days after cessation of therapy or had fewer than 2 postbaseline visits >6 months apart. Insufficiently represented therapies are those with fewer than 200 recorded treatment discontinuation events (alemtuzumab: 101; cladribine: 36; daclizumab: 13; ocrelizumab: 3; and rituximab: 26). EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting multiple sclerosis.